The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines

Carreño, Juan Manuel; Dambrauskas, Nicholas; Garcia-Sastre, Adolfo; Gleason, Charles; Gonzalez, Irene; Gupta, Sneh Lata; Kawabata, Hisaaki; Krammer, Florian; Martinez, Jose Luis; Muangnoicharoen, Sant; Palese, Peter; Pitisuttithum, Punnee; Raghunandan, Rama; Raskin, Ariel; Sather, D. Noah; Simon, Viviana; Singh, Gagandeep; Slamanig, Stefan; Srivastava, Komal; Sun, Weina; Suthar, Mehul S.; Tcheou, Johnstone; Vigdorovich, Vladimir; Wirachwong, Ponthip; Wrammert, Jens

The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines

Abstract

NDV-HXP-S is a recombinant Newcastle disease virus based-vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be produced in embryonated chicken eggs using the same process as that employed for the production of influenza virus vaccines. Here we performed a secondary analysis of the antibody responses after vaccination with inactivated NDV-HXP-S in a Phase I clinical study in Thailand. Please click Download on the upper right corner to see the full abstract

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Engineering Conferences International

oai:dc.engconfintl.org:vaccine...

Last time updated on 27/10/2022